Indegene Ltd

Indegene Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Indegene Ltd

₹ 640 0.79%
21 Nov 4:00 p.m.
indegene.com BSE: 544172 NSE: INDGN
About

It is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way.

Key Points

Business Divison[1]
A) Enterprise Commercial Solutions aids life science companies in optimizing digital marketing operations, driving scale efficiency, and implementing technology-enabled personalization strategies for engagement with HCPs, patients, and operations.

Website BSE NSE
  • Market Cap ₹ 15,323 Cr.
  • Current Price ₹ 640
  • High / Low ₹ 737 / 469
  • Stock P/E 41.3
  • Book Value ₹ 98.6
  • Dividend Yield 0.00 %
  • ROCE 29.0 %
  • ROE 26.9 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 88.5% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 29.2%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Healthcare Industry: Miscellaneous

Part of BSE Healthcare Nifty Smallcap 250 BSE IPO BSE Allcap Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
632 608 636 673 673 676 687
535 511 515 524 534 548 561
Operating Profit 97 97 121 149 139 129 126
OPM % 15% 16% 19% 22% 21% 19% 18%
13 28 12 13 26 22 21
Interest 12 13 12 12 12 12 4
Depreciation 20 20 20 18 18 20 19
Profit before tax 79 92 101 132 134 120 124
Tax % 38% 26% 25% 25% 29% 27% 26%
49 68 75 99 95 88 92
EPS in Rs 2.20 3.08 3.38 4.45 4.26 3.67 3.83
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
553 643 966 1,665 2,306 2,590 2,710
511 499 736 1,378 1,910 2,084 2,167
Operating Profit 42 144 230 287 396 505 543
OPM % 8% 22% 24% 17% 17% 20% 20%
7 -102 -3 -21 58 79 83
Interest 6 9 7 6 31 49 40
Depreciation 17 19 26 33 60 76 76
Profit before tax 26 14 195 226 363 459 510
Tax % 45% 191% 23% 28% 27% 27%
14 -12 149 163 266 337 373
EPS in Rs 89.98 -40.20 951.96 937.73 11.99 15.14 16.21
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 36%
3 Years: 39%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: 88%
3 Years: 32%
TTM: 26%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 29%
Last Year: 27%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 0.31 0.31 0.31 0.35 44 44 48
Reserves 73 -105 324 764 1,020 1,385 2,312
147 483 51 66 502 490 88
108 222 220 524 638 627 576
Total Liabilities 329 600 596 1,353 2,204 2,546 3,024
104 119 86 138 664 646 632
CWIP 0 0 0 0 0 0 0
Investments 0 13 0 120 614 796 917
225 468 510 1,096 926 1,103 1,475
Total Assets 329 600 596 1,353 2,204 2,546 3,024

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
65 22 172 297 130 508
-18 -16 -81 -158 -896 -326
-21 136 -132 233 333 -66
Net Cash Flow 25 143 -40 373 -433 115

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 60 127 108 97 102 91
Inventory Days
Days Payable
Cash Conversion Cycle 60 127 108 97 102 91
Working Capital Days 23 64 53 16 45 40
ROCE % 37% 55% 46% 33% 29%

Shareholding Pattern

Numbers in percentages

1 Recently
Jun 2024Sep 2024
3.79% 4.82%
3.84% 3.17%
92.38% 92.01%
No. of Shareholders 2,03,5991,51,440

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls